Online inquiry

IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3253MR)

This product GTTS-WQ3253MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Lombar radicular pain research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3253MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13856MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ9887MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ10572MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ15588MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ12739MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ4732MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ13253MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ4206MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW